NIPH Clinical Trials Search

THe effect of canagliflozin on active GLP-1 levels and betatrophin in patients with type 2 diabetes (CANARIA-STUDY)

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	Type 2 diabetes
Date of first enrollment	2015/02/15
Target sample size	40
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	3 days canagliflozin (100 mg 1x before breakfast) treatment with diet treatment Thereafter addition of teneligliptin (20 mg 1x before breakfast) for 3 days 3 days diet treatment Thereafter addition of teneligliptin (20 mg 1x before breakfast) for 3 days

Outcome(s)

Primary Outcome	Fasting plasma glucose, glucose after meal test, active plasma GLP-1 level, active serum betatrophin level
Secondary Outcome	Plasma GIP level

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1)Patients with type 1 diabetes, pancreatic diabetes or secondary diabetes (Cushing syndrome, acromegaly etc.) diabetic coma or diabetic pre-coma, or type 1 diabetes 2)Patients who are not candidated for canagliflozin or teneligliptin treatment 3)Patients under insulin treatment 4)Heavy alcohol consumer (more than or equal to 60 g/day of pure alcohol ) 5)Patients under pregnancy, possible pregnancy, or lactation 6)Patients with severe renal dysfunction (Cr >2.4 mg/dL or Ccr <30 mL/min) 7)Furthermore, patients judged as inadequacy for participation in this study by medical doctor